PDF(Pubmed)
Abstract：
BACKGROUND: This is the first report of an ROS1-CENPW fusion gene in pancreatic malignancies.
METHODS: A 77-year-old woman with a pancreatic tumor and multiple liver metastases was admitted to our hospital. Genetic testing revealed the presence of the ROS1-CENPW fusion gene, a rare fusion gene that has not been previously reported in the field of pancreatic cancer. The patient received crizotinib plus AG (albumin paclitaxel plus gemcitabine) chemotherapy. After treatment, the patient\'s condition stabilized, and her prognosis was good.
CONCLUSIONS: The ROS1-CENPW gene treatment regimen used in this case is an excellent treatment option that provides new hope for patients with advanced pancreatic cancer and similar genetic mutations. To date, owing to the rarity of the ROS1-CENPW fusion gene, our team has encountered only a single case. Therefore, the efficacy of crizotinib plus AG chemotherapy in patients with pancreatic acinar cell carcinoma harboring the ROS1-CENPW fusion gene requires further validation.
METHODS: A 77-year-old woman with a pancreatic tumor and multiple liver metastases was admitted to our hospital. Genetic testing revealed the presence of the ROS1-CENPW fusion gene, a rare fusion gene that has not been previously reported in the field of pancreatic cancer. The patient received crizotinib plus AG (albumin paclitaxel plus gemcitabine) chemotherapy. After treatment, the patient\'s condition stabilized, and her prognosis was good.
CONCLUSIONS: The ROS1-CENPW gene treatment regimen used in this case is an excellent treatment option that provides new hope for patients with advanced pancreatic cancer and similar genetic mutations. To date, owing to the rarity of the ROS1-CENPW fusion gene, our team has encountered only a single case. Therefore, the efficacy of crizotinib plus AG chemotherapy in patients with pancreatic acinar cell carcinoma harboring the ROS1-CENPW fusion gene requires further validation.
摘要：
背景：这是ROS1-CENPW融合基因在胰腺恶性肿瘤中的首次报道。
方法：我院收治一名77岁女性，患有胰腺肿瘤和多发性肝转移。基因检测显示ROS1-CENPW融合基因的存在,一种罕见的融合基因，以前在胰腺癌领域没有报道过。患者接受克唑替尼加AG（白蛋白紫杉醇加吉西他滨）化疗。治疗后,患者病情稳定,而且她的预后很好.
结论：在这种情况下使用的ROS1-CENPW基因治疗方案是一种极好的治疗选择，为晚期胰腺癌和类似基因突变的患者提供了新的希望。迄今为止,由于ROS1-CENPW融合基因的稀有，我们团队只遇到过一个案例。因此,对于携带ROS1-CENPW融合基因的胰腺腺泡细胞癌患者,克唑替尼联合AG化疗的疗效需要进一步验证.
方法：我院收治一名77岁女性，患有胰腺肿瘤和多发性肝转移。基因检测显示ROS1-CENPW融合基因的存在,一种罕见的融合基因，以前在胰腺癌领域没有报道过。患者接受克唑替尼加AG（白蛋白紫杉醇加吉西他滨）化疗。治疗后,患者病情稳定,而且她的预后很好.
结论：在这种情况下使用的ROS1-CENPW基因治疗方案是一种极好的治疗选择，为晚期胰腺癌和类似基因突变的患者提供了新的希望。迄今为止,由于ROS1-CENPW融合基因的稀有，我们团队只遇到过一个案例。因此,对于携带ROS1-CENPW融合基因的胰腺腺泡细胞癌患者,克唑替尼联合AG化疗的疗效需要进一步验证.
